ATE174794T1 - Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien - Google Patents

Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien

Info

Publication number: ATE174794T1
Authority: AT; Austria
Prior art keywords: arginine; animal; hypotension; free; treatment
Prior art date: 1991-09-27

Application number

AT92922032T

Other languages

English (en)

Inventor

Robert G Kilbourn

Owen W Griffith

Steven S Gross

Original Assignee

Univ Texas

Cornell Res Foundation Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-27

Filing date

1992-09-26

Publication date

1999-01-15

1991-09-27 Priority claimed from US07/767,265 external-priority patent/US5286739A/en

1992-06-23 Priority claimed from US07/902,653 external-priority patent/US5374651A/en

1992-06-30 Priority claimed from US07/910,868 external-priority patent/US5334380A/en

1992-09-26 Application filed by Univ Texas, Cornell Res Foundation Inc filed Critical Univ Texas

1999-01-15 Application granted granted Critical

1999-01-15 Publication of ATE174794T1 publication Critical patent/ATE174794T1/de

Links

208000001953 Hypotension Diseases 0.000 title abstract 5
230000036543 hypotension Effects 0.000 title abstract 5
150000001413 amino acids Chemical class 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
239000000203 mixture Substances 0.000 abstract 8
238000009472 formulation Methods 0.000 abstract 7
238000000034 method Methods 0.000 abstract 4
238000011282 treatment Methods 0.000 abstract 4
206010040070 Septic Shock Diseases 0.000 abstract 3
230000036303 septic shock Effects 0.000 abstract 3
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
230000002959 anti-hypotensive effect Effects 0.000 abstract 2
229940124572 antihypotensive agent Drugs 0.000 abstract 2
230000015572 biosynthetic process Effects 0.000 abstract 2
238000011321 prophylaxis Methods 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
239000004475 Arginine Substances 0.000 abstract 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 abstract 1
102000000589 Interleukin-1 Human genes 0.000 abstract 1
108010002352 Interleukin-1 Proteins 0.000 abstract 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 abstract 1
102000000588 Interleukin-2 Human genes 0.000 abstract 1
108010002350 Interleukin-2 Proteins 0.000 abstract 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
206010054094 Tumour necrosis Diseases 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
150000001484 arginines Chemical class 0.000 abstract 1
230000008512 biological response Effects 0.000 abstract 1
230000000973 chemotherapeutic effect Effects 0.000 abstract 1
229960002173 citrulline Drugs 0.000 abstract 1
235000013477 citrulline Nutrition 0.000 abstract 1
239000002158 endotoxin Substances 0.000 abstract 1
238000005755 formation reaction Methods 0.000 abstract 1
239000003407 interleukin 1 receptor blocking agent Substances 0.000 abstract 1
239000003607 modifier Substances 0.000 abstract 1
235000016709 nutrition Nutrition 0.000 abstract 1
229960003104 ornithine Drugs 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000035488 systolic blood pressure Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT92922032T 1991-09-27 1992-09-26 Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien ATE174794T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/767,265 US5286739A (en)	1991-09-27	1991-09-27	Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US07/902,653 US5374651A (en)	1991-09-27	1992-06-23	Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
US07/910,868 US5334380A (en)	1991-09-27	1992-06-30	Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
PCT/US1992/008227 WO1993005780A1 (en)	1991-09-27	1992-09-26	Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies

Publications (1)

Publication Number	Publication Date
ATE174794T1 true ATE174794T1 (de)	1999-01-15

Family

ID=27419635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92922032T ATE174794T1 (de)	1991-09-27	1992-09-26	Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien

Country Status (7)

Country	Link
EP (1)	EP0663826B1 (de)
JP (1)	JPH06510769A (de)
AT (1)	ATE174794T1 (de)
AU (1)	AU664210B2 (de)
CA (1)	CA2116684A1 (de)
DE (1)	DE69228006T2 (de)
WO (1)	WO1993005780A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5334380A (en) *	1991-09-27	1994-08-02	Board Of Regents, The University Of Texas System	Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5356873A (en) *	1992-11-05	1994-10-18	Clintec Nutrition Co.	Method for providing nutritional requirements to patients having a chronic inflammation reaction
AU5040493A (en) *	1992-11-30	1994-06-09	Transcend Therapeutics, Inc	Method for treating systemic inflammatory response syndrome
US5312831A (en) *	1993-05-12	1994-05-17	American Cyanamid Company	Urethanes and ureas that induce cytokine production
DE4407484A1 (de) *	1993-12-03	1995-06-08	Werner Prof Dr Kreutz	Medikament zur Krebs-Therapie
GB9512100D0 (en) *	1995-06-14	1995-08-09	Sandoz Nutrition Ltd	Improvements in or relating to organic compounds
ES2145997T3 (es) *	1995-02-23	2000-07-16	Novartis Nutrition Ag	Composiciones de aminoacidos y uso de las mismas en la nutricion clinica.
US5656608B1 (en) *	1995-02-23	2000-09-26	Novartis Nutrition Ltd	Amino acid compositions and methods of treatment using same
US6284219B1 (en)	1998-06-30	2001-09-04	Phenome Sciences Inc.	In vivo determination of metabolic function for use in therapy management
IT1320782B1 (it) *	2000-07-04	2003-12-10	Professional Dietetics Srl	Composizioni a base di aminoacidi, atte al trattamentodell'insufficienza cardiaca.
US20090291877A1 (en) *	2006-04-04	2009-11-26	Nicolaas Emile Deutz	Treatments using citrulline
EP2771029A4 (de)	2011-10-25	2015-07-01	Onclave Therapeutics Ltd	Antikörperformulierungen und verfahren dafür
JP2016132622A (ja) *	2015-01-16	2016-07-25	イーエヌ大塚製薬株式会社	敗血症治療又は予防用栄養組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2516027A1 (de) *	1973-04-30	1975-10-16	Univ Johns Hopkins	Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper
WO1988008259A1 (fr) *	1987-05-01	1988-11-03	Otsuka Pharmaceutical Co., Ltd.	Preparation d'emulsion nutritive
FR2615734B1 (fr) *	1987-05-27	1989-12-01	Synthelabo	Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie
SE8704217D0 (sv) *	1987-10-29	1987-10-29	Vinnars Erik Ab	Aminosyrakomposition for parenteral neringstillforsel
US5006559A (en) *	1988-08-31	1991-04-09	Clintec Nutrition Co.	Method of use of branched-chain amino acids infusions to influence appetite
US4957938A (en) *	1989-06-21	1990-09-18	Abbott Laboratories	Nutritional formulation for the treatment of renal disease

1992
- 1992-09-26 AT AT92922032T patent/ATE174794T1/de not_active IP Right Cessation
- 1992-09-26 DE DE69228006T patent/DE69228006T2/de not_active Expired - Fee Related
- 1992-09-26 JP JP5505589A patent/JPH06510769A/ja active Pending
- 1992-09-26 AU AU28662/92A patent/AU664210B2/en not_active Ceased
- 1992-09-26 WO PCT/US1992/008227 patent/WO1993005780A1/en not_active Ceased
- 1992-09-26 EP EP92922032A patent/EP0663826B1/de not_active Expired - Lifetime
- 1992-09-26 CA CA002116684A patent/CA2116684A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2116684A1 (en)	1993-04-01
JPH06510769A (ja)	1994-12-01
DE69228006D1 (de)	1999-02-04
EP0663826A1 (de)	1995-07-26
AU2866292A (en)	1993-04-27
EP0663826B1 (de)	1998-12-23
DE69228006T2 (de)	1999-08-12
WO1993005780A1 (en)	1993-04-01
AU664210B2 (en)	1995-11-09

Legal Events

Date	Code	Title	Description
1999-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
Bauer et al.	1982	SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action
ATE174794T1 (de)	1999-01-15	Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
CA1329543C (en)	1994-05-17	Human growth hormone formulation
Brunda et al.	1984	Inhibition of experimentally‐induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases
RU97110125A (ru)	1999-05-27	Ацилированные аналоги инсулина
KR880000098A (ko)	1988-03-23	콘드로이틴 설페이트 면역자극 조성물
CA2215203A1 (en)	1996-09-19	Vaccines for plague
ATE75945T1 (de)	1992-05-15	Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
DE69228474D1 (de)	1999-04-01	STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER
AU2000277238A1 (en)	2001-10-15	Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
AU7589587A (en)	1987-07-28	Low dosage of interferon to enhance vaccine efficiency
SE8802569D0 (sv)	1988-07-08	Improvements in or relation to somatostatins
JPS5998019A (ja)	1984-06-06	インタ−フエロンの相乗効果
EP0563212A1 (de)	1993-10-06	Synthetische immunoaktive peptide mit immunmodulierenden und therapeutischen wirkungen
BR0207704A (pt)	2004-07-06	Alfa interferon modificado com imunogenicidade reduzida
CA2098726A1 (en)	1992-06-20	Use of il-4 to enhance immune response to immunogens in vaccines
IL161665A0 (en)	2004-09-27	Method of administering a thymosin alpha 1 peptide
RU95120588A (ru)	1998-01-10	Циклогексапептиды, их смеси, способ их получения и применения
DE68916237T2 (de)	1994-11-10	Stabilisierte interleukin-1-beta enthaltende zusammensetzung.
Castaigne et al.	1989	Hairy cell leukemia: follow-up after completion of alpha interferon treatment
KR870010080A (ko)	1987-11-30	면역촉진 활성을 갖는 트리펩티드
Wakitani et al.	1985	Vasodilator properties of a family of bioactive atrial peptides in isolated perfused rat kidneys
Rosti et al.	1989	In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome
Gurskaia et al.	1989	Recovery of impaired respiratory activity in cats by thyroliberin analog (PR-546) devoid of hormonal properties
王小马	1988	ELECTROIMPULSE ACUPUNCTURE TREATMENT OF 110 CASES OF ABDOMINAL PAIN AS A SEOUELA OF ABDOMINAL SURGERY